EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.897
https://www.valueinhealthjournal.com/article/S1098-3015(22)03101-1/fulltext
Title :
EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03101-1&doi=10.1016/j.jval.2022.09.897
First page :
Section Title :
Open access? :
No
Section Order :
10443